Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI)
prnewswire.com/news-releases/synthetic-biolog...Posted Jan 5, 2017, 10:32 PM UTC
53
prnewswire.com
Loading comments…
Posted Jan 5, 2017, 10:32 PM UTC